drugset / Trial / NCT00776867
Study of Single Agent Perifosine for Recurrent Pediatric Solid Tumors
Phase 1
Completed
38 enrolled
Memorial Sloan Kettering Cancer Center
AEterna Zentaris · collabDuke University · collabUniversity of Wisconsin, Madison · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to test whether perifosine- a drug that inhibits the protein AKT, and has had some success in the treatment of adult cancers- is safe and effective in treating cancer. The investigators want to find out what effects, good and/or bad, it has on the patient and the cancer. The investigators are testing different dose schedules of perifosine and the patient will be asked to partake in one of the dose schedules.
Timeline
- Start
- 2008-10
- Primary completion
- 2017-07
- Completion
- 2017-07
Publications
- Kushner BH, Cheung NV, Modak S, Becher OJ, Basu EM, Roberts SS, Kramer K, Dunkel IJ. A phase I/Ib trial targeting the Pi3k/Akt pathway using perifosine: Long-term progression-free survival of patients with resistant neuroblastoma. Int J Cancer. 2017 Jan 15;140(2):480-484. doi: 10.1002/ijc.30440. Epub 2016 Sep 30.
- Sun W, Modak S. Emerging treatment options for the treatment of neuroblastoma: potential role of perifosine. Onco Targets Ther. 2012;5:21-9. doi: 10.2147/OTT.S14578. Epub 2012 Mar 2.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Perifosine | Small molecule | 50 mg/m2 | Oral |
| Subject | Perifosine | Small molecule | 75 mg/m2 | Oral |